Active Ingredient History

  • Now
Rofecoxib is a nonsteroidal anti-inflammatory drug which selectively inhibits COX-2 and subsequent prostaglandin synthesis. The drug was developed by Merk and approved by FDA in 1999 for relief of signs and symptoms of arthritis, acute pain in adults, and painful menstrual cycles under the name Vioxx. Later on Merck voluntarily withdrawn Vioxx from the market due to safety concerns (high risk of heart attack and stroke).   NCATS

  • SMILES: CC(C)(N)CNC(=O)C[C@@H]1CC[C@@]2(CC1)OO[C@]3(O2)C4CC5CC(CC3C5)C4
  • Mol. Mass: 392.54
  • ALogP: 3.25
  • ChEMBL Molecules:
More Chemistry
4-(4-methylsulfonylphenyl)-3-phenyl-5h-furan-2-one | cahill may roberts brand of rofecoxib | ceeoxx | merck brand of rofecoxib | merck frosst brand of rofecoxib | merck sharp & dhome brand of rofecoxib | mk 0966 | mk-0966 | mk-1966 | mk 966 | mk-966 | msd brand of rofecoxib | refecoxib | rofecoxib | vioxx | vioxx dolor


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue